Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
12.85
-0.43 (-3.28%)
Apr 25, 2025, 11:40 AM EDT - Market open
Capricor Therapeutics Revenue
In the year 2024, Capricor Therapeutics had annual revenue of $22.27M, down -11.55%. Capricor Therapeutics had revenue of $11.13M in the quarter ending December 31, 2024, a decrease of -7.92%.
Revenue (ttm)
$22.27M
Revenue Growth
-11.55%
P/S Ratio
21.00
Revenue / Employee
$139,190
Employees
160
Market Cap
586.72M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 22.27M | -2.91M | -11.55% |
Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
CAPR News
- 5 weeks ago - Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 6 weeks ago - FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment - PRNewsWire
- 7 weeks ago - Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025 - GlobeNewsWire
- 7 weeks ago - Capricor: Further Value Unlocked With Priority Review Of Deramiocel - Seeking Alpha
- 7 weeks ago - Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition - Benzinga
- 2 months ago - Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data - Seeking Alpha